New UniSC clinical trial aims to reduce risk factor in heart disease, stroke | UniSC | University of the Sunshine Coast, Queensland, Australia

Accessibility links

New UniSC clinical trial aims to reduce risk factor in heart disease

Researchers at the University of the Sunshine Coast are trialling a potential new treatment to reduce high levels of a blood lipoprotein that can lead to clogged arteries and cardio-cerebrovascular disease.

The injection targets Lipoprotein (a), which is an independent risk factor for cardio-cerebrovascular disease caused by hardened arteries.

Trial participants will attend 14 visits and spend two nights at UniSC Clinical Trials’ Morayfield clinic over a 12-month period.

Principal Investigator Dr Chris Moller said cholesterol-lowering medications did not affect Lipoprotein (a) and its levels in the blood were determined by genetic factors.

“The levels are unaffected by diet, lifestyle or environment,” Dr Moller said.

“Surprisingly, one in five individuals is estimated to have elevated lipoprotein (a), with many remaining unaware of their condition.”

The trial will assess the investigational treatment’s safety, side effects and tolerability in participants with elevated lipoprotein (a).

“We’re looking for people between 18 and 65 years of age to participate in the trial,” said Clinical Trial Coordinator Meghna Areekal.

Eligible participants must have a body mass index of 18 to 35 with a body weight over 50kg.

Those interested in participating can find more information at or call (07) 5409 8640.

Media enquiries: Please contact the Media Team